Further studies are needed to investigate the efficacy and safety of olverembatinib in combination with other chemotherapies in AP-CML and BCR-ABL1T315I mutation patients. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.